%0 Journal Article
%T The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer
%A Zuzana Kolkova
%A Vera Cassl¨¦n
%A Emir Henic
%A Sara Ahmadi
%A Anna Ehinger
%A Karin Jirstr£¿m
%A Bertil Cassl¨¦n
%J Journal of Ovarian Research
%D 2012
%I BioMed Central
%R 10.1186/1757-2215-5-9
%X GPER mRNA was assayed with quantitative real-time PCR (qPCR) in 42 primary ovarian tumors and 7 ovarian cancer cell lines. ER¦Á and ER¦Â mRNA were analyzed for comparison. GPER protein was semi-quantified with densitometric scanning of Western blots and its tissue distribution analyzed with immunohistochemistry (IHC) in 40 ovarian tumors. In addition, IHC was evaluated in a tissue microarray (TMA) of 150 primary malignant ovarian tumors.All tumor samples contained GPER mRNA. The content of mRNA was not different between benign and malignant tumors, but one third of malignant samples over-expressed GPER mRNA. The content of ER¦Á mRNA was higher in malignant than in benign tumors, whereas ER¦Â mRNA was higher in benign than in malignant tumors. GPER mRNA was detected in all seven ovarian cancer cell lines with highest levels in TOV21G and TOV112D cells. Similar expression pattern was seen for ER¦Â mRNA. Western blot demonstrated GPER protein in all tumor samples. Semi-quantification showed no difference between benign and malignant tumors, but about one third of malignant samples over-expressed GPER protein. GPER staining was localized mainly in epithelial cells. In the TMA study we found no correlation between GPER staining and clinical stage, histological grade or patient survival.GPER mRNA as well as GPER protein is present in both benign and malignant ovarian tumor tissue. About one third of malignant tumors over-expressed both GPER mRNA and protein. This, however, correlated neither with histological or clinical parameters nor with patient survival.Epidemiologic data suggest on the one hand that estradiol taken as oral contraceptive in the premenopause decreases the risk of ovarian cancer, while taken as hormone therapy in the postmenopause increases that risk. From a clinical perspective, development and progression of ovarian tumors are not generally considered estrogen sensitive, as is the case for breast and endometrial cancer. However, some experimental data chal
%K ER¦Á
%K ER¦Â
%K borderline tumors
%K TMA
%K immunohistochemistry
%K ovarian cancer cell lines
%U http://www.ovarianresearch.com/content/5/1/9